A Medicare beneficiary who has both severe obesity and one of the medical conditions that GLP-1 drugs are approved to treat can be disqualified from the $50 monthly price on those same drugs. That design feature, buried in the fine print of the Medicare GLP-1 Bridge, is now producing denials, and KFF Health News has documented the mechanism in detail.
The rule works like this. The $50 Bridge price applies only when a GLP-1 is prescribed solely for weight loss. Anyone carrying a diagnosis that the Food and Drug Administration has approved these drugs to treat, such as type 2 diabetes or moderate to severe obstructive sleep apnea, is routed back to their own Part D plan instead, where copays commonly run several hundred dollars a month.
For households budgeting on a fixed retirement income, the practical consequences are stark. Two people with identical body mass indices and identical prescriptions can pay $50 or several hundred dollars, depending on what else is written in their charts.
Diagnosis That Costs a Patient the Discount
Jeff La Marca, a 68-year-old retired professor in Basking Ridge, New Jersey, received a Zepbound prescription in January and could not afford the roughly $750 monthly price. When the Bridge launched, he applied. He was denied.
La Marca has severe obstructive sleep apnea, one of several diagnoses that remove a patient from the Bridge price. The notification did not explain the reason. He believes he would have qualified on weight alone. "And yet I can't get it. I'm livid," he told KFF Health News, describing a body mass index of 42, quadruple heart bypass surgery, stroke risk, and prediabetes.
The logic behind the design is not arbitrary. The Bridge was "designed to target those people who can't get GLP-1 coverage through Part D," said Juliette Cubanski, who directs the Program on Medicare Policy at KFF. Federal law has long barred Medicare from covering drugs prescribed solely for weight loss, and the Bridge is an 18-month pilot built to fill precisely that statutory hole. KFF has separately estimated the eligible population at about 3.8 million people.
The pilot covers three drugs: Wegovy, the KwikPen formulation of Zepbound, and the oral medication Foundayo. Beneficiaries must be enrolled in Part D, though the preauthorization request is submitted to a separate system operated by a contractor for the Centers for Medicare and Medicaid Services rather than to the insurer. Many people with a body mass index of 35 or higher qualify, and those with a body mass index of 27 to 34 can qualify if they also have certain conditions such as prediabetes or cardiovascular disease.
The gap between that intent and the patient experience is where the problem sits. Coverage exists on paper for patients like La Marca. Affordability does not.
The Cost Gap That Coverage Does Not Close
Taylor Lacy, a primary care physician at Sunflower Medical Group in Roeland Park, Kansas, described the pattern she sees at the pharmacy counter. "Coverage doesn't always mean affordable," she told KFF Health News.
Lacy said many Medicare patients navigate prior authorization and months of step therapy, trying cheaper alternatives first, only to reach the counter and find copays of $200 to $600 a month or more. She said the Bridge leaves behind patients with the greatest medical need.
Published analyses of GLP-1 coverage in Medicare have found rising out-of-pocket costs and near-universal prior authorization requirements. Chris Bond, a spokesperson for the insurance trade group AHIP, attributed the underlying problem to manufacturer pricing, "which they alone set and they alone can lower."
CMS reports the demonstration is running smoothly on its own terms. Agency spokesperson Timothy Foster said the initial weeks have been positive, most prior authorization requests have been completed in under 12 hours, and thousands of eligible beneficiaries have obtained GLP-1 medications at pharmacies nationwide.
Cubanski has projected that if a quarter of the 3.8 million eligible people enroll and stay on treatment for the full 18 months, the cost to Medicare would be about $3.3 billion. If three quarters enroll, that could reach $10 billion. Expanding eligibility to the additional 5.9 million overweight beneficiaries already covered by Part D GLP-1 coverage would add billions more. The federal government has not published its own cost estimate.
Ground That Shifted Since MedicalDaily's Earlier Report
MedicalDaily previously reported on the launch of the Medicare GLP-1 Bridge in July, covering who qualified and how the flat $50 copay worked. That reporting explained that beneficiaries already receiving a GLP-1 through Part D were excluded, and that the copay does not count toward the Part D out-of-pocket cap.
What is new is the diagnosis-based routing and its scale. The earlier coverage did not establish that holding an FDA-approved indication for these drugs, rather than existing coverage for them, is itself disqualifying, nor did it establish that roughly 5.9 million beneficiaries fall into that category. The new reporting adds a documented denial, the CMS response on processing times, and independent cost projections.
The broader structural warning MedicalDaily reported earlier still stands. The Bridge runs for 18 months from its July launch, and the permanent replacement model has been delayed, leaving beneficiaries who start treatment now uncertain about what follows.
Steps for Patients Caught in the Gap
Nobody should stop or start a prescription based on a coverage rule without talking to their clinician. GLP-1 medications require medical supervision, and abrupt changes carry their own risks.
For beneficiaries who were denied or expect to be, several avenues exist. Ask the prescriber to confirm exactly which diagnosis triggered the routing back to Part D, since the denial notice may not say. Request the Part D plan's formulary and tier placement in writing to see the actual copay before assuming it is unaffordable. If the drug is covered but the cost-sharing is prohibitive, ask about the plan's exception and appeals process, which is a formal right under Part D, not a favor.
Beneficiaries can also ask about manufacturer patient assistance programs, though eligibility rules for people with Medicare coverage vary and should be confirmed directly. A State Health Insurance Assistance Program counselor can review plan options at no cost, and Medicare open enrollment, from October 15 to December 7, is the window to compare how plans will cover these drugs next year.
Congressional action would be required to make weight loss drug coverage a permanent Medicare benefit. Whether CMS narrows or clarifies the diagnosis exclusion, and whether any successor to the Bridge is finalized before it expires, are the next developments worth watching.
Key Questions Answered
What is the exclusion everyone is talking about? The $50 Bridge price applies only when a GLP-1 is prescribed solely for weight loss. A beneficiary who has a condition the FDA has approved these drugs to treat, such as type 2 diabetes or moderate to severe obstructive sleep apnea, is routed to their Part D plan instead, where copays can run into the hundreds.
How many people does this affect? KFF Health News reports an estimated 5.9 million Medicare enrollees fall outside the Bridge because of such a diagnosis. About 3.8 million beneficiaries are estimated to meet the Bridge criteria.
Why was the program designed this way? Federal law bars Medicare from covering drugs prescribed solely for weight loss. The Bridge was built to fill that specific hole, so people who already have a coverage pathway through Part D were directed there.
Does being routed to Part D mean no coverage at all? No. Part D can cover the drug. The issue is cost sharing, which one physician quoted in the reporting described as commonly running $200 to $600 a month or more after prior authorization and step therapy.
Can a denial be appealed? Part D has a formal exceptions and appeals process that beneficiaries can use when a drug is covered, but cost sharing or restrictions are a barrier. Ask the prescriber and the plan to start it in writing rather than by phone alone.
Should anyone stop taking a GLP-1 due to coverage issues? No one should start, stop or change a prescription without talking to a qualified clinician. Coverage questions and clinical decisions should be handled separately.
Which drugs does the pilot cover? Three: Wegovy, the KwikPen formulation of Zepbound, and the oral medication Foundayo. The pilot runs for 18 months, and making weight loss drug coverage permanent in Medicare would require action from Congress.
